JP6602840B2 - 可溶性グアニル酸シクラーゼの活性化因子としてのヘテロ環式カルボン酸 - Google Patents

可溶性グアニル酸シクラーゼの活性化因子としてのヘテロ環式カルボン酸 Download PDF

Info

Publication number: JP6602840B2
Authority: JP; Japan
Prior art keywords: mmol; mixture; reduced pressure; under reduced; solution
Prior art date: 2014-07-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

JP2017503554A

Other languages

English (en)

Japanese (ja)

Other versions

JP2017521457A (ja

JP2017521457A5 (2

Inventor

ジェロッドバーネットブレネマン

ジョンデイヴィッドジン

クリストファーロナルドサルコ

ジョンウェストブルック

チョンフアチャン

マオリンユー

タマラデニスホプキンス

マイケルディーロウ

Original Assignee

ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-07-22

Filing date

2015-07-21

Publication date

2019-11-06

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53783363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6602840(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-07-21 Application filed by ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング filed Critical ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング

2017-08-03 Publication of JP2017521457A publication Critical patent/JP2017521457A/ja

2018-08-30 Publication of JP2017521457A5 publication Critical patent/JP2017521457A5/ja

2019-11-06 Application granted granted Critical

2019-11-06 Publication of JP6602840B2 publication Critical patent/JP6602840B2/ja

Status Active legal-status Critical Current

2035-07-21 Anticipated expiration legal-status Critical

Links

BSQCXINEMYRJIT-GWDUEUPMSA-N CCOC([C@@](C1)(CC2)C1CN2c1nc(-c2cc(C)ccc2OCc(cc2CCN3C4CCOCC4)ccc2C3=O)c[s]1)=O Chemical compound CCOC([C@@](C1)(CC2)C1CN2c1nc(-c2cc(C)ccc2OCc(cc2CCN3C4CCOCC4)ccc2C3=O)c[s]1)=O BSQCXINEMYRJIT-GWDUEUPMSA-N 0.000 description 1
RIRFEZHUBITAIH-SHCORVSCSA-N Cc(cc1)cc(-c2c[s]c(N(CC3[C@@H]4C3)CC4OC=O)n2)c1OCc(cc1CCN2C3CCOCC3)ccc1C2=O Chemical compound Cc(cc1)cc(-c2c[s]c(N(CC3[C@@H]4C3)CC4OC=O)n2)c1OCc(cc1CCN2C3CCOCC3)ccc1C2=O RIRFEZHUBITAIH-SHCORVSCSA-N 0.000 description 1
OBSLLHNATPQFMJ-UHFFFAOYSA-N Cc1c[s]c(C)n1 Chemical compound Cc1c[s]c(C)n1 OBSLLHNATPQFMJ-UHFFFAOYSA-N 0.000 description 1
KIASRXUIWJUEIR-RZLLJLAESA-N Cc1cccc(-c2nc(N(C[C@@H]3C4)[C@H](COC)[C@]34C(O)=O)ccc2)c1OCc1cc(C)c(CN(CC2)C3CCOCC3)c2c1 Chemical compound Cc1cccc(-c2nc(N(C[C@@H]3C4)[C@H](COC)[C@]34C(O)=O)ccc2)c1OCc1cc(C)c(CN(CC2)C3CCOCC3)c2c1 KIASRXUIWJUEIR-RZLLJLAESA-N 0.000 description 1
OISVCGZHLKNMSJ-UHFFFAOYSA-N Cc1cccc(C)n1 Chemical compound Cc1cccc(C)n1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Reproductive Health (AREA)
Ophthalmology & Optometry (AREA)
Dermatology (AREA)
Gynecology & Obstetrics (AREA)
Cardiology (AREA)
Obesity (AREA)
Psychiatry (AREA)
Psychology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Pulmonology (AREA)
Gastroenterology & Hepatology (AREA)
Emergency Medicine (AREA)

JP2017503554A 2014-07-22 2015-07-21 可溶性グアニル酸シクラーゼの活性化因子としてのヘテロ環式カルボン酸 Active JP6602840B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201462027376P	2014-07-22	2014-07-22
US62/027,376		2014-07-22
PCT/US2015/041245 WO2016014463A1 (en)	2014-07-22	2015-07-21	Heterocyclic carboxylic acids as activators of soluble guanylate cyclase

Publications (3)

Publication Number	Publication Date
JP2017521457A JP2017521457A (ja)	2017-08-03
JP2017521457A5 JP2017521457A5 (2)	2018-08-30
JP6602840B2 true JP6602840B2 (ja)	2019-11-06

Family

ID=53783363

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2017503554A Active JP6602840B2 (ja)	2014-07-22	2015-07-21	可溶性グアニル酸シクラーゼの活性化因子としてのヘテロ環式カルボン酸

Country Status (26)

Country	Link
US (1)	US9353090B2 (2)
EP (1)	EP3172202B1 (2)
JP (1)	JP6602840B2 (2)
KR (1)	KR20170035993A (2)
CN (1)	CN106459017B (2)
AP (1)	AP2016009615A0 (2)
AR (1)	AR101265A1 (2)
AU (1)	AU2015292833B2 (2)
BR (1)	BR112017000943A2 (2)
CA (1)	CA2955937A1 (2)
CL (1)	CL2017000071A1 (2)
CO (1)	CO2017000438A2 (2)
DK (1)	DK3172202T3 (2)
EA (1)	EA032972B1 (2)
ES (1)	ES2784477T3 (2)
HU (1)	HUE049231T2 (2)
IL (1)	IL249587A0 (2)
MX (1)	MX378717B (2)
PE (1)	PE20170249A1 (2)
PH (1)	PH12017500111A1 (2)
PL (1)	PL3172202T3 (2)
PT (1)	PT3172202T (2)
SG (2)	SG11201700507XA (2)
TW (1)	TWI711615B (2)
UY (1)	UY36226A (2)
WO (1)	WO2016014463A1 (2)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2017216429B2 (en) *	2016-02-01	2022-10-06	Cyclerion Therapeutics, Inc.	Use of sGC stimulators for the treatment of Nonalcoholic Steatohepatitis (NASH)
EP3512825B1 (en)	2016-09-14	2020-10-21	Genomatica, Inc.	1,3-fatty diol compounds and derivatives thereof
CN109890379A (zh)	2016-10-11	2019-06-14	拜耳制药股份公司	包含sGC活化剂和盐皮质激素受体拮抗剂的组合产品
CN106495999B (zh) *	2016-10-18	2019-08-16	亳州学院	一种芳香醛及其合成方法
US12491261B2 (en)	2016-10-26	2025-12-09	Acuitas Therapeutics, Inc.	Lipid nanoparticle formulations
AR112392A1 (es)	2017-07-14	2019-10-23	Glaxosmithkline Ip Dev Ltd	Compuesto tricíclico de pirazol, su uso para fabricar un medicamento y composición farmaceutica que lo comprende
EP4501322A3 (en) *	2017-08-17	2025-04-16	Acuitas Therapeutics, Inc.	Lipids for use in lipid nanoparticle formulations
WO2019081456A1 (en)	2017-10-24	2019-05-02	Bayer Aktiengesellschaft	USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT
EP3498298A1 (en)	2017-12-15	2019-06-19	Bayer AG	The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi)
EP3784238A4 (en) *	2018-04-27	2021-12-29	Hetero Labs Ltd.	Process for preparation of ((3r,11br)-1,3,4,6,7,11b-hexahydro-9,10-di(methoxy-d)-3-(2-methylpropyl)-2h-benzo[a]quinolizin-2-one
EP3787610A1 (en)	2018-04-30	2021-03-10	Bayer Aktiengesellschaft	The use of sgc activators and sgc stimulators for the treatment of cognitive impairment
EP3793553A1 (en)	2018-05-15	2021-03-24	Bayer Aktiengesellschaft	1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
EP3574905A1 (en)	2018-05-30	2019-12-04	Adverio Pharma GmbH	Method of identifying a subgroup of patients suffering from dcssc which benefits from a treatment with sgc stimulators and sgc activators in a higher degree than a control group
CA3116576A1 (en)	2018-10-18	2020-04-23	Acuitas Therapeutics, Inc.	Lipids for lipid nanoparticle delivery of active agents
US12234217B2 (en)	2018-12-03	2025-02-25	Fmc Corporation	Method for preparing N-phenylpyrazole-1-carboxamides
US20220128561A1 (en)	2019-01-17	2022-04-28	Bayer Aktiengesellschaft	Methods to determine whether a subject is suitable of being treated with an agonist of soluble gyanylyl cyclase (sgc)
EP4010333A1 (en)	2019-08-09	2022-06-15	Kalvista Pharmaceuticals Limited	Plasma kallikrein inhibitors
ES3054438T3 (en)	2020-07-16	2026-02-03	Acuitas Therapeutics Inc	Cationic lipids for use in lipid nanoparticles
CN114957087A (zh) *	2022-04-13	2022-08-30	湖南复瑞生物医药技术有限责任公司	一种帕罗韦德中间体制备方法
EP4536205A1 (en)	2022-06-09	2025-04-16	Bayer Aktiengesellschaft	Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women
CN117384082A (zh) *	2022-07-20	2024-01-12	杭州国瑞生物科技有限公司	一种6,6-二甲基-3-氮杂双环[3.1.0]己烷的合成方法
CN120225203A (zh)	2022-11-04	2025-06-27	勃林格殷格翰国际有限公司	用于治疗系统性硬化症的可溶性鸟苷酸环化酶活化剂

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040067938A1 (en)	2000-09-29	2004-04-08	Penglie Zhang	Quaternary amines and related inhibitors of factor xa
AU2006272088A1 (en)	2005-07-18	2007-01-25	Bayer Schering Pharma Aktiengesellschaft	Novel use of activators and stimulators of soluble guanylate cyclase for the prevention or treatment of renal disorders
US20080045560A1 (en)	2006-08-15	2008-02-21	Wyeth	Pyrrolidine and related derivatives useful as PR modulators
AU2008250643A1 (en)	2007-05-12	2008-11-20	Bayer Schering Pharma Aktiengesellschaft	sGC stimulators, sGC activators and combinations for the treatment of urological disorders
BRPI0816382A2 (pt)	2007-09-06	2015-02-24	Merck Sharp & Dohme	Composto, composição, e, métodos para ativar a guanilato ciclase solúvel e para tratar ou previnir doenças
WO2009043495A1 (en)	2007-10-05	2009-04-09	Sanofi-Aventis Deutschland Gmbh	Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid n-phenylamides in the treatment of pain
WO2009068652A1 (en)	2007-11-30	2009-06-04	Smithkline Beecham Corporation	2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines as soluble guanylate cyclase activators
TW200938529A (en)	2007-12-03	2009-09-16	Smithkline Beecham Corp	Compounds
CA2720343A1 (en)	2008-04-04	2009-10-08	Takeda Pharmaceutical Company Limited	Heterocyclic derivative and use thereof
WO2010015652A2 (en)	2008-08-07	2010-02-11	Smithkline Beecham Corporation	Thiazole compounds as activators of soluble guanylate cyclase
WO2010015653A1 (en)	2008-08-07	2010-02-11	Smithkline Beecham Corporation	Pyrimidine derivatives as activators of soluble guanylate cyclase
AU2009322836B2 (en)	2008-11-25	2013-04-04	Merck Sharp & Dohme Corp.	Soluble guanylate cyclase activators
JP5780430B2 (ja)	2009-01-17	2015-09-16	アドヴェリオ・ファーマ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	勃起不全の処置用のＰＤＥ５阻害剤と組み合わせたｓＧＣ刺激剤またはｓＧＣ活性化剤
KR20110133034A (ko)	2009-02-26	2011-12-09	머크 샤프 앤드 돔 코포레이션	가용성 구아닐레이트 시클라제 활성화제
CN102770133A (zh)	2010-02-05	2012-11-07	拜耳知识产权有限责任公司	用于治疗囊性纤维化的单独和与PDE5抑制剂组合的sGC刺激剂或sGC激活剂
WO2011095553A1 (en)	2010-02-05	2011-08-11	Bayer Schering Pharma Aktiengesellschaft	Sgc stimulators or sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction
HRP20150987T1 (hr)	2010-05-26	2015-10-23	Adverio Pharma Gmbh	UPORABA sGC STIMULATORA, sGC AKTIVATORA, SAMOSTALNO I U KOMBINACIJAMA S INHIBITORIMA PDE5 ZA LIJEÄŚENJE SISTEMSKE SKLEROZE (SSc)
EP2687210A1 (de)	2010-06-25	2014-01-22	Bayer Intellectual Property GmbH	Verwendung von Stimulatoren und Aktivatoren der löslichen Guanylatzyklase zur Behandlung von Sichelzellanämie und Konservierung von Blutersatzstoffen
EP2632551B1 (en)	2010-10-28	2016-07-06	Merck Sharp & Dohme Corp.	Soluble guanylate cyclase activators
JP5715713B2 (ja) *	2011-03-10	2015-05-13	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	可溶性グアニル酸シクラーゼ活性化因子
US8815857B2 (en)	2011-08-12	2014-08-26	Boehringer Ingelheim International Gmbh	Soluble guanylate cyclase activators
EP2594270A3 (en)	2011-11-18	2013-07-31	BIP Patents	The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc)
HRP20191755T1 (hr) *	2012-09-07	2019-12-27	Boehringer Ingelheim International Gmbh	Alkoksipirazoli kao aktivatori topljive gvanilat ciklaze
WO2015095515A1 (en)	2013-12-20	2015-06-25	Novartis Ag	Sgc activators for the treatment of glaucoma

2015
- 2015-07-21 PL PL15747311T patent/PL3172202T3/pl unknown
- 2015-07-21 AP AP2016009615A patent/AP2016009615A0/en unknown
- 2015-07-21 ES ES15747311T patent/ES2784477T3/es active Active
- 2015-07-21 CA CA2955937A patent/CA2955937A1/en not_active Abandoned
- 2015-07-21 CN CN201580033515.4A patent/CN106459017B/zh active Active
- 2015-07-21 TW TW104123596A patent/TWI711615B/zh not_active IP Right Cessation
- 2015-07-21 SG SG11201700507XA patent/SG11201700507XA/en unknown
- 2015-07-21 AU AU2015292833A patent/AU2015292833B2/en not_active Ceased
- 2015-07-21 DK DK15747311.7T patent/DK3172202T3/da active
- 2015-07-21 JP JP2017503554A patent/JP6602840B2/ja active Active
- 2015-07-21 AR ARP150102304A patent/AR101265A1/es unknown
- 2015-07-21 US US14/804,363 patent/US9353090B2/en active Active
- 2015-07-21 PT PT157473117T patent/PT3172202T/pt unknown
- 2015-07-21 SG SG10201806565SA patent/SG10201806565SA/en unknown
- 2015-07-21 EA EA201790246A patent/EA032972B1/ru not_active IP Right Cessation
- 2015-07-21 PE PE2017000087A patent/PE20170249A1/es unknown
- 2015-07-21 KR KR1020177004761A patent/KR20170035993A/ko not_active Withdrawn
- 2015-07-21 MX MX2017000926A patent/MX378717B/es unknown
- 2015-07-21 BR BR112017000943A patent/BR112017000943A2/pt not_active Application Discontinuation
- 2015-07-21 WO PCT/US2015/041245 patent/WO2016014463A1/en not_active Ceased
- 2015-07-21 HU HUE15747311A patent/HUE049231T2/hu unknown
- 2015-07-21 EP EP15747311.7A patent/EP3172202B1/en active Active
- 2015-07-22 UY UY0001036226A patent/UY36226A/es unknown
2016
- 2016-12-15 IL IL249587A patent/IL249587A0/en unknown
2017
- 2017-01-11 CL CL2017000071A patent/CL2017000071A1/es unknown
- 2017-01-18 PH PH12017500111A patent/PH12017500111A1/en unknown
- 2017-01-19 CO CONC2017/0000438A patent/CO2017000438A2/es unknown

Also Published As

Publication number	Publication date
HUE049231T2 (hu)	2020-09-28
PE20170249A1 (es)	2017-04-05
AU2015292833B2 (en)	2019-11-28
MX2017000926A (es)	2017-05-04
PL3172202T3 (pl)	2020-07-13
MX378717B (es)	2025-03-10
CL2017000071A1 (es)	2017-06-30
SG11201700507XA (en)	2017-02-27
IL249587A0 (en)	2017-02-28
JP2017521457A (ja)	2017-08-03
BR112017000943A2 (pt)	2017-11-14
CO2017000438A2 (es)	2017-08-31
TWI711615B (zh)	2020-12-01
KR20170035993A (ko)	2017-03-31
AU2015292833A1 (en)	2016-12-22
AP2016009615A0 (en)	2016-12-31
CA2955937A1 (en)	2016-01-28
ES2784477T3 (es)	2020-09-28
PT3172202T (pt)	2020-05-06
AR101265A1 (es)	2016-12-07
SG10201806565SA (en)	2018-08-30
CN106459017A (zh)	2017-02-22
WO2016014463A1 (en)	2016-01-28
EA032972B1 (ru)	2019-08-30
US20160024059A1 (en)	2016-01-28
CN106459017B (zh)	2020-07-17
PH12017500111A1 (en)	2017-05-29
US9353090B2 (en)	2016-05-31
EP3172202A1 (en)	2017-05-31
EP3172202B1 (en)	2020-01-29
EA201790246A1 (ru)	2017-07-31
TW201617340A (zh)	2016-05-16
DK3172202T3 (da)	2020-04-27
UY36226A (es)	2016-01-29

Legal Events

Date	Code	Title	Description
2018-07-23	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180723
2018-07-23	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180723
2019-03-19	A977	Report on retrieval	Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190319
2019-03-28	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190328
2019-06-28	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190628
2019-09-24	TRDD	Decision of grant or rejection written
2019-10-03	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20191003
2019-10-17	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20191009
2019-10-18	R150	Certificate of patent or registration of utility model	Ref document number: 6602840 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150
2022-03-28	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2023-10-12	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2024-10-23	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2025-10-16	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250

Publication	Publication Date	Title
JP6602840B2 (ja)	2019-11-06	可溶性グアニル酸シクラーゼの活性化因子としてのヘテロ環式カルボン酸
JP5970134B2 (ja)	2016-08-17	可溶性グアニル酸シクラーゼ活性化因子としてのアルコキシピラゾール
EP2683710B1 (en)	2017-07-19	Soluble guanylate cyclase activators
JP5826393B2 (ja)	2015-12-02	可溶性グアニル酸シクラーゼ活性化因子
CN104011052B (zh)	2016-06-08	化合物
CN103596952B (zh)	2016-05-04	作为Syk抑制剂的新型取代的吡啶并吡嗪类化合物
TW202122391A (zh)	2021-06-16	Ｒｉｐ１抑制性化合物及用於製備和使用其之方法後補
TWI617551B (zh)	2018-03-11	新穎吡啶衍生物
WO2018065962A1 (en)	2018-04-12	Substituted pyrrolidines and their use in the treatment of cystic fiibrosis
TWI833819B (zh)	2024-03-01	用於治療與apj受體活性相關的病狀的化合物及組成物
HK1210178A1 (en)	2016-04-15	Substituted pyridopyrazines as syk inhibitors
TW202317560A (zh)	2023-05-01	Ｃｄｋ２抑制劑及其使用方法
JPWO2019189555A1 (ja)	2021-04-15	複素環化合物
WO2023098825A1 (zh)	2023-06-08	Sos1抑制剂、包含其的药物组合物及其用途
CN119053596A (zh)	2024-11-29	作为激酶抑制剂的杂环化合物、其组合物及使用方法
HK1210164B (en)	2019-05-24	Alkoxy pyrazoles as soluble guanylate cyclase activators
CN104812753A (zh)	2015-07-29	作为Syk抑制剂的取代吡啶并吡嗪类化合物
HK1190143B (en)	2017-02-24	Substituted pyridopyrazines as novel syk inhibitors